These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9853846)

  • 1. Critical ovarian hyperstimulation syndrome in a coasted in-vitro fertilization patient.
    Tortoriello DV; McGovern PG; Colon JM; Loughlin J; Santoro N
    Hum Reprod; 1998 Nov; 13(11):3005-8. PubMed ID: 9853846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
    Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
    Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation syndrome?
    Lee C; Tummon I; Martin J; Nisker J; Power S; Tekpetey F
    Hum Reprod; 1998 May; 13(5):1157-8. PubMed ID: 9647538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postparacentesis bilateral massive vulvar edema in a patient with severe ovarian hyperstimulation syndrome.
    Vavilis D; Tzitzimikas S; Agorastos T; Loufopoulos A; Tsalikis T; Bontis JN
    Fertil Steril; 2002 Apr; 77(4):841-3. PubMed ID: 11937145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study.
    Egbase PE; Sharhan MA; Grudzinskas JG
    Hum Reprod; 1999 Jun; 14(6):1421-5. PubMed ID: 10357951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study.
    Waldenström U; Kahn J; Marsk L; Nilsson S
    Hum Reprod; 1999 Feb; 14(2):294-7. PubMed ID: 10099966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Coasting" does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients.
    Tortoriello DV; McGovern PG; Colón JM; Skurnick JH; Lipetz K; Santoro N
    Fertil Steril; 1998 Mar; 69(3):454-60. PubMed ID: 9531876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization.
    de Jong D; Macklon NS; Mannaerts BM; Coelingh Bennink HJ; Fauser BC
    Hum Reprod; 1998 Mar; 13(3):573-5. PubMed ID: 9572414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of high initial daily doses of gonadotropin in patients with poor ovarian reserve.
    Chou LL; Hwu YM; Lin MH; Lin SY; Lee RK
    Taiwan J Obstet Gynecol; 2010 Dec; 49(4):442-8. PubMed ID: 21199746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer.
    Sher G; Salem R; Feinman M; Dodge S; Zouves C; Knutzen V
    Obstet Gynecol; 1993 Jun; 81(6):1009-11. PubMed ID: 8497341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.
    Sher G; Zouves C; Feinman M; Maassarani G
    Hum Reprod; 1995 Dec; 10(12):3107-9. PubMed ID: 8822423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study to determine whether serum follicle-stimulating hormone can be a marker for ovarian hyperresponse to follicle-maturing drugs for in vitro fertilization.
    Check JH; Pesso R; Peymer M
    Gynecol Obstet Invest; 1997; 43(4):242-4. PubMed ID: 9194622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone.
    Weissman A; Barash A; Shapiro H; Casper RF
    Hum Reprod; 1998 Dec; 13(12):3421-4. PubMed ID: 9886527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers.
    Queenan JT; Veeck LL; Toner JP; Oehninger S; Muasher SJ
    Hum Reprod; 1997 Jul; 12(7):1573-6. PubMed ID: 9262299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian hyperstimulation syndrome following the sole administration of injectable gonadotropin-releasing hormone agonist (triptorelin) for the pituitary down-regulation and in vitro fertilization treatment: report of two cases.
    Qublan HS; Beni-Merei Z; Megdadi M; Al-Quraan G
    Arch Gynecol Obstet; 2009 Feb; 279(2):221-3. PubMed ID: 18461341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.